Navigation Links
Stason Pharmaceuticals Inc. announces Kansas City expansion, adds human health capabilities
Date:11/8/2013

KANSAS CITY, Kan., Nov. 8, 2013 /PRNewswire/ -- Stason Pharmaceuticals, Inc. announced today that it is expanding into Kansas City by moving its brand division from Irvine, Calif. to Kansas City, Kan.  A new entity has been developed, KC Specialty Therapeutics LLC, in which the new assets will be placed to focus on research and development of new chemical entities for humans.

"Stason Pharmaceuticals has been very impressed with the biosciences opportunities in the Kansas City region since moving Stason Animal Health's national headquarters here earlier this year," said Diana Wood, vice president of corporate development for Stason Pharmaceuticals and CEO for KC Specialty Therapeutics LLC. "The KC Animal Health Corridor and broader life sciences community have been incredibly supportive."

Today's announcement comes just 90 days after Stason Pharmaceutical's animal division, Stason Animal Health, announced it was relocating its corporate headquarters to the KC Animal Health Corridor.

KC Specialty Therapeutics LLC will locate alongside Stason Animal Health at the Bioscience & Technology Business Center located on the University of Kansas Medical Center campus.  Over the next year, the company will create job opportunities in Kansas City and continue to grow its presence over time.

"We are thrilled that Stason Pharmaceuticals values our region's strong biosciences business environment," said Bob Marcusse, president and CEO, Kansas City Area Development Council. "We look forward to seeing both Stason Pharmaceuticals and KC Specialty Therapeutics grow in our region."

About Stason Pharmaceuticals
Stason Pharmaceuticals entered the commercial generic market in 1994 and today continues to manufacture and market these products through a global network of distributors. Stason entered the contract manufacturing arena in 2000 to provide manufacturing support to other pharmaceutical companies, and in 2008, Stason launched its Brand Division. Headquartered in Southern California, the Stason group employs approximately 120 people worldwide. http://www.stasonpharma.com/

About KC Specialty Therapeutics LLC
KC Specialty Pharma is focused on the development of new chemical entities in human orphan drug indications for which there is no available treatment.  Orphan drugs are defined as those that treat less than 200,000 in the US. 

About Greater Kansas City
Home to 2.5 million people, the Kansas City region offers the benefits of more than 50 unique communities and 18 counties in Kansas and Missouri.  www.thinkKC.com


'/>"/>
SOURCE Kansas City Area Development Council
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
2. Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
3. ProVen Pharmaceuticals Participates in the Dolphins Cycling Challenge
4. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
5. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
6. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
7. Vanda Pharmaceuticals Reports Third Quarter 2013 Results
8. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
9. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
11. Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 2016 , The data will be ... # 8006)   The conclusions of the study ... treated patients with 90% of the m presenting ... . Seventy two percent of the patients had clinical benefit. ... results from a Phase I study of plitidepsin in combination with bortezomib and ...
(Date:5/19/2016)... , May 19, 2016 ... titled, World Biopsy Devices Market Opportunities and Forecasts, ... devices market generated $1,621 million in 2015. The ... 2015, and is expected to maintain this trend ... http://photos.prnewswire.com/prnh/20140911/647229 ) , To ...
(Date:5/19/2016)... 19, 2016 MGB Biopharma, ... of Anti-infectives, Welcomes the Final Instalment of Lord ... Today   Lord Jim O,Neill,s ... final recommendations, providing a comprehensive action plan for ... the rising threat of superbugs - something that ...
Breaking Medicine Technology:
(Date:5/23/2016)... ... May 23, 2016 , ... Four Circles Recovery Center, a leading treatment center ... announce the launch of its new extended care program, Fifth Circle. Available for clients ... Circles or another primary treatment program, Fifth Circle is designed to foster the recovery ...
(Date:5/23/2016)... ... 23, 2016 , ... Bio-Optronics, Inc. is delighted to announce ... its recent and anticipated growth. , Max Elbaz was appointed as Vice President, ... segments. Max joined the Bio-Optronics team in March. His areas of expertise include ...
(Date:5/23/2016)... Plano, TX (PRWEB) , ... May 23, 2016 , ... ... Analytics’ on June 10, 2016 from 11:00 AM – 12:00 PM ET. To ... GlobalHealth’s decision to start a proactive outreach program built on Big Data with a ...
(Date:5/23/2016)... ... , ... Celebrating their 20th anniversary this year, Metcal Technologies ... MadgeTech data loggers. These qualifications translate to excellent customer service for the life ... and valued distributors. , Metcal is now offering the RFC1000 Cloud Relay ...
(Date:5/23/2016)... ... ... announced today the upcoming airing of Innovations with Ed ... 2016 at 4:00pET via Fox Business. , The show ... innovation to safely and rapidly develop cures for mosquito-borne, ...
Breaking Medicine News(10 mins):